ANI Pharmaceuticals (ANIP) CEO Nikhil Lalwani Sells 5,400 Shares

What Happened

• Nikhil Lalwani, President & CEO and a director of ANI Pharmaceuticals (ANIP), sold 5,400 shares on 2026-08-25 in an open-market sale. The weighted average sale price was $74.30 per share, for total proceeds of approximately $401,220. This was a sale (not a purchase), which is commonly routine trading by insiders.

Key Details

• Transaction date: 2026-08-25; filing date: 2026-08-26 (timely filing).
• Shares sold: 5,400; weighted average price: $74.30; total proceeds: ~$401,220.
• Price range: individual trades executed between $73.58 and $74.61 (weighted avg reported).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: Sale was effected under a Rule 10b5-1 trading plan adopted May 26, 2026 (prearranged). Multiple trades produced the reported weighted-average price.
• Transaction code: S = Sale.

Context

• The sale was executed under a 10b5-1 plan, meaning the trades were preplanned and may have been scheduled in advance of this reporting date; such plans reduce but do not eliminate inference about the insider’s motives.
• As this was a sale (not a purchase or option exercise), it does not signal the same level of insider conviction that a purchase might; retail investors should consider this alongside other insider activity and company fundamentals.